Phospho-ESR1 (Tyr537) Antibody

What is the significance of ESR1 Tyr537 phosphorylation in estrogen receptor biology?

Phosphorylation at tyrosine 537 (Tyr537) of the estrogen receptor alpha (ESR1) plays a crucial role in regulating receptor activity, nuclear localization, and transcriptional function. This site is located within the ligand binding domain (amino acids 501-550) and represents a critical post-translational modification that influences receptor conformation. Phosphorylation at this residue enhances transcriptional activity of ESR1 and affects its interaction with coactivator proteins. Studies have demonstrated that Tyr537 phosphorylation status impacts hormone binding, dimerization, and hormone-dependent transcriptional activity . The significance of this phosphorylation site is further emphasized by the fact that mutations at this position (Y537S, Y537N, Y537C) are frequently observed in hormone-resistant breast cancers, highlighting its role in endocrine therapy response .

How does a Phospho-ESR1 (Tyr537) antibody differ from standard ESR1 antibodies?

While standard ESR1 antibodies detect total estrogen receptor alpha protein regardless of its phosphorylation status, Phospho-ESR1 (Tyr537) antibodies specifically recognize ESR1 only when phosphorylated at tyrosine 537. This specificity is achieved through the use of immunogens consisting of synthesized phosphopeptides derived from the human ER-alpha sequence surrounding the phosphorylation site (typically P-L-Y(p)-D-L) . This selective detection allows researchers to:

• Distinguish between phosphorylated and non-phosphorylated forms of ESR1

• Study the dynamic regulation of ESR1 activity through site-specific phosphorylation

• Investigate signaling pathways that modulate ESR1 function through this specific modification

• Correlate Tyr537 phosphorylation status with clinical outcomes and treatment responses

The specificity of these antibodies is typically validated through immunoneutralization experiments with excess phospho-peptide versus non-phospho-peptide to confirm selective binding to the phosphorylated form .

What are the recommended applications for Phospho-ESR1 (Tyr537) antibodies?

Phospho-ESR1 (Tyr537) antibodies are versatile tools that can be employed in multiple experimental techniques. Based on manufacturer specifications and published research, the recommended applications include:

For optimal results, researchers should:

• Validate antibody specificity using appropriate controls (e.g., phosphatase treatment, competing peptides)

• Optimize dilution factors for specific experimental conditions and sample types

• Include phosphorylation site mutants (Y537F/A) as negative controls where possible

• Consider the preservation of phospho-epitopes during sample preparation

How should I validate a Phospho-ESR1 (Tyr537) antibody for immunohistochemistry of clinical breast cancer samples?

Proper validation of Phospho-ESR1 (Tyr537) antibodies for immunohistochemistry (IHC) on clinical breast cancer specimens requires a systematic approach:

• Positive and negative tissue controls:

  • Test the antibody on known ESR1-positive breast cancer samples

  • Include ESR1-negative breast cancer specimens as negative controls

  • Compare staining patterns with total ESR1 antibodies on serial sections

• Peptide competition assays:

  • Perform immunoabsorption with excess phospho-peptide (~30× excess)

  • Use non-phospho-peptide as a control competitor

  • Validate specificity by demonstrating loss of nuclear staining with phospho-peptide but not with non-phospho-peptide competition

• Subcellular localization assessment:

  • Verify that nuclear staining is predominant (where activated ESR1 is expected)

  • Note that some cytoplasmic staining may persist despite phospho-peptide neutralization

  • Document any differential localization patterns compared to total ESR1

• Correlation with other phosphorylation sites:

  • Compare p-Y537-ERα expression with other known phosphorylated sites (e.g., p-T311-ERα, p-S559-ERα)

  • Evaluate relationships between multiple phosphorylation sites as potential "phosphorylation codes"

• Clinical correlation validation:

  • Assess associations with established clinicopathological parameters

  • Evaluate correlation with treatment outcomes in appropriate cohorts

This validation approach is supported by published methodologies that demonstrated p-Y537-ERα antibody specificity through selective loss of nuclear (but not cytoplasmic) staining following phospho-peptide neutralization .

What are the critical factors for preserving phospho-epitopes during sample preparation for Phospho-ESR1 (Tyr537) detection?

Preserving phospho-epitopes during sample preparation is crucial for accurate detection of Phospho-ESR1 (Tyr537). Key considerations include:

• Tissue collection and fixation:

  • Minimize warm ischemia time (<30 minutes)

  • Use phosphatase inhibitors immediately during tissue collection

  • Fix tissues in 10% neutral-buffered formalin for 24-48 hours (not prolonged)

  • Consider alternative fixatives specifically optimized for phospho-epitope preservation

• Protein extraction for Western blotting:

  • Include phosphatase inhibitor cocktails in all lysis buffers

  • Maintain samples at 4°C throughout processing

  • Avoid repeated freeze-thaw cycles

  • Use freshly prepared lysis buffers

• Antigen retrieval for IHC:

  • Optimize pH conditions (typically pH 6.0 citrate or pH 9.0 EDTA buffers)

  • Test both heat-induced and enzymatic retrieval methods

  • Avoid over-retrieval which can destroy phospho-epitopes

  • Include phosphatase inhibitors in retrieval solutions

• Storage considerations:

  • Store antibodies at -20°C as recommended by manufacturers

  • Avoid repeated freeze-thaw cycles by preparing single-use aliquots

  • For tissue samples, consider whether frozen or FFPE preservation better maintains the specific phospho-epitope

• Blocking endogenous phosphatases:

  • Include sodium fluoride (50 mM) and sodium orthovanadate (1 mM) in buffers

  • Consider microcystin-LR for serine/threonine phosphatase inhibition

  • Add inhibitors fresh before each experiment

Research has shown that phospho-tyrosine epitopes can be particularly labile, requiring careful optimization of each step in the protocol to ensure reliable detection .

How do I determine the optimal dilution of Phospho-ESR1 (Tyr537) antibody for my specific experimental system?

Determining the optimal dilution of Phospho-ESR1 (Tyr537) antibody requires systematic titration and validation within your specific experimental system:

• Initial range determination:

  • Start with the manufacturer's recommended dilution ranges:

    • Western Blot: 1:500-1:2000

    • IHC: 1:100-1:300

    • IF: 1:50-1:200

    • ELISA: 1:10000

• Titration approach:

  • Prepare a dilution series spanning 2-fold dilutions above and below the recommended range

  • Test each dilution on positive control samples with known p-Y537-ERα expression

  • Include negative controls (phosphatase-treated samples or Y537F mutants)

• Signal-to-noise optimization:

  • Evaluate specific signal intensity versus background staining

  • Select the dilution providing maximum specific signal with minimal background

  • Consider signal linearity for quantitative applications

• Sample-specific considerations:

  • Cell lines may require different antibody concentrations than tissue sections

  • Fresh tissues may differ from archived FFPE samples

  • Species cross-reactivity may necessitate different dilutions for human versus mouse samples

• Validation of selected dilution:

  • Confirm specificity using phospho-peptide competition

  • Verify detection is lost following phosphatase treatment

  • Compare results with published patterns of Tyr537 phosphorylation

The optimal dilution should provide clear discrimination between phosphorylated and non-phosphorylated ESR1, with minimal cross-reactivity to other phospho-proteins .

How can Phospho-ESR1 (Tyr537) antibodies be used to study the relationship between ESR1 phosphorylation and hormone resistance in breast cancer?

Phospho-ESR1 (Tyr537) antibodies serve as valuable tools for investigating the complex relationship between ESR1 phosphorylation and hormone resistance in breast cancer through multiple research approaches:

• Clinical correlation studies:

  • Analyze p-Y537-ERα levels in primary versus metastatic breast cancer tissues

  • Compare phosphorylation status between hormone-sensitive and resistant tumors

  • Correlate p-Y537-ERα expression with clinical outcomes in patients receiving endocrine therapy

  • Studies have demonstrated that nuclear p-Y537-ERα expression is positively associated with positive lymph nodes (Spearman r = 0.20, P = 0.0002) and large tumor size (r = 0.13, P = 0.02)

• Mechanistic investigations:

  • Examine the impact of phosphatases like PTPH1 that dephosphorylate ER at Tyr537

  • Research has shown that PTPH1 increases breast cancer sensitivity to tamoxifen and fulvestrant by dephosphorylating ERα at Tyr537

  • Study how Tyr537 phosphorylation affects ER nuclear accumulation and transcriptional activity

• Mutation versus phosphorylation analyses:

  • Compare functional differences between Y537 phosphorylation and Y537S/N mutations

  • Investigate whether phosphorylation precedes mutation in therapy resistance evolution

  • The Tyr537Asn ER mutant possesses potent, estradiol-independent transcriptional activity compared to wild-type ER and remains largely unaffected by estradiol, tamoxifen, or pure antiestrogens like ICI 164,384

• Therapeutic targeting strategies:

  • Test whether inhibiting kinases responsible for Tyr537 phosphorylation restores hormone sensitivity

  • Evaluate whether phosphorylation status predicts response to novel SERDs or SERMs

  • Assess if combined targeting of phosphorylation and other ER-regulatory mechanisms enhances therapeutic efficacy

What is the relationship between ESR1 Tyr537 phosphorylation and ESR1 mutations in hormone-resistant breast cancer?

The relationship between ESR1 Tyr537 phosphorylation and mutations at the same site represents a fascinating aspect of hormone resistance development in breast cancer:

• Structural and functional parallels:

  • Both Tyr537 phosphorylation and mutations (Y537S/N/C) promote constitutive ER activity

  • Molecular dynamics simulations demonstrate that Y537S mutations induce conformational changes that mimic those caused by phosphorylation

  • Both mechanisms lead to estrogen-independent transcriptional activation and reduced antiestrogen sensitivity

• Evolutionary relationship:

  • Evidence suggests phosphorylation may represent an initial adaptive response to estrogen deprivation

  • Mutations may provide a more stable mechanism for constitutive activation under selection pressure

  • Y537S/N mutations are among the most frequent ESR1 mutations in hormone-resistant breast cancer

• Differential response to therapies:

  • Phosphorylation is potentially reversible through phosphatase activity (e.g., PTPH1)

  • Mutations confer more permanent resistance, with Y537S showing the greatest resistance to SERDs, SERMs, and novel agents like SERCAs

  • Comparative data show that the Y537S mutation has the most stable active conformational change due to a novel hydrogen bond

• Detection and monitoring implications:

  • Combined analysis of phosphorylation status and mutation screening may provide better prediction of therapy response

  • Circulating tumor DNA (ctDNA) analysis for ESR1 mutations shows moderate concordance (44%) with tissue mutation status

  • Phosphorylation analysis requires tissue samples while mutations can be monitored through liquid biopsies

The interplay between these mechanisms suggests potential sequential evolution from phosphorylation-mediated activation to mutation-driven constitutive activity during therapy resistance development .

How do different ESR1 mutations at the Tyr537 position affect antibody recognition and experimental design?

ESR1 mutations at Tyr537 present specific challenges for antibody recognition and necessitate careful experimental design considerations:

• Impact on antibody epitope recognition:

  • Phospho-specific antibodies (p-Tyr537) will not recognize mutant forms where tyrosine is replaced (Y537S/N/C)

  • Total ESR1 antibodies targeting regions containing the mutation may show altered affinity

  • Mutation-specific antibodies have been developed for some common variants (e.g., Y537S-specific)

• Experimental design adaptations:

  • When studying mixed populations, use complementary detection methods:

    • DNA sequencing to identify mutations

    • Phospho-antibodies to detect wild-type phosphorylated receptor

    • Mutation-specific antibodies when available

  • Consider downstream effects (target gene expression) as functional readouts

• Validation strategies for mixed populations:

  • Genotype cell lines or tissues prior to phosphorylation studies

  • Use mutation-specific control samples (e.g., MCF-7 cells with CRISPR-introduced Y537S)

  • Implement digital PCR for sensitive detection of low-frequency mutations

  • ddPCR has been used to assess specific ESR1 hotspots: Y537S, Y537C, Y537N, D538G, E380Q

• Quantification challenges:

  • In heterogeneous samples, phospho-antibody signals may not correlate with total activity

  • Correcting for mutation frequency is essential when interpreting phosphorylation data

  • Consider using mass spectrometry approaches for unbiased detection of all forms

Research indicates that different Y537 mutations confer varying degrees of constitutive activity and resistance to therapies, with Y537S typically showing the strongest phenotype compared to Y537N or Y537C .

How does Tyr537 phosphorylation integrate with other post-translational modifications of ESR1 to form a "phosphorylation code"?

Tyr537 phosphorylation functions within a complex network of post-translational modifications (PTMs) on ESR1, collectively forming what researchers describe as a "phosphorylation code" that fine-tunes receptor function:

• Coordinated multi-site phosphorylation:

  • p-Y537-ERα positively correlates with p-T311-ERα (Spearman r = 0.41, P < 0.0001) and p-S559-ERα (Spearman r = 0.24, P < 0.0001) in breast cancer tissues

  • Cases with high p-T311-ERα show significantly higher p-Y537-ERα expression (median IHC score 180 versus 40, P < 0.0001)

  • Similarly, high p-S559-ERα cases exhibit higher p-Y537-ERα levels (median IHC score 90 versus 25, P < 0.0001)

• Interplay with other PTM types:

  • Phosphorylation at Tyr537 occurs within a broader context of ESR1 modifications including:

    • Phosphorylation by cyclin A/CDK2 and CK1 at other sites

    • Glycosylation (O-linked N-acetylglucosamine)

    • Ubiquitination (regulated by LATS1 via DCAF1, STUB1/CHIP, and UBR5)

    • Methylation (dimethylation by PRMT1 at Arg-260)

    • Palmitoylation (by ZDHHC7 and ZDHHC21)

• Functional integration of PTMs:

  • Phosphorylation at Tyr537 impacts:

    • Nuclear localization (potentially counteracted by Arg-260 methylation)

    • Coactivator recruitment (affecting UBR5-mediated degradation)

    • Membrane association (coordinated with palmitoylation)

  • Different PTM combinations may direct ESR1 to distinct subcellular compartments and functional states

• Therapeutic implications:

  • Targeting enzymes that regulate the "phosphorylation code" may offer alternative strategies to direct ESR1 inhibition

  • PTPH1 overexpression enhances breast cancer sensitivity to tamoxifen and fulvestrant by dephosphorylating Tyr537

  • Combined inhibition of multiple PTM-regulating enzymes may prevent compensatory activation mechanisms

This integrated view of ESR1 PTMs suggests that comprehensive profiling of multiple modifications may provide better predictive biomarkers for therapy response than single-site analysis .

What are the kinases and phosphatases that regulate ESR1 Tyr537 phosphorylation, and how might they be targeted therapeutically?

The dynamic regulation of ESR1 Tyr537 phosphorylation involves specific kinases and phosphatases that represent potential therapeutic targets:

• Identified regulators:

  • Phosphatases:

    • PTPH1 (Protein-tyrosine phosphatase H1) directly dephosphorylates ER at Tyr537 in vitro and in breast cancer cells

    • PTPH1 depends on its catalytic activity to stimulate ER nuclear accumulation and enhance breast cancer sensitivity to antiestrogens

  • Kinases:

    • While over 10 kinases participate in phosphorylating various ER sites, those specific to Tyr537 remain incompletely characterized

    • Src family kinases have been implicated in phosphorylating tyrosine residues on ESR1

• Phosphorylation-mediated functional changes:

  • Tyr537 phosphorylation enhances:

    • Transcriptional activity

    • Hormone-independent activation

    • Altered coregulator recruitment

  • Dephosphorylation by PTPH1 promotes:

    • ER nuclear accumulation

    • Increased sensitivity to tamoxifen and fulvestrant

• Therapeutic targeting strategies:

  • Phosphatase enhancement:

    • Strategies to increase PTPH1 expression or activity may restore antiestrogen sensitivity

    • PTPH1 activators could complement direct ER-targeting approaches

  • Kinase inhibition:

    • Identification and targeting of kinases that phosphorylate Tyr537

    • Combination of kinase inhibitors with conventional antiestrogens

  • Rational drug combinations:

    • Dual targeting of phosphorylation machinery and ER degradation

    • Sequential therapy to prevent emergence of resistant clones

• Clinical development considerations:

  • Phosphorylation biomarkers may identify patients suitable for specific therapeutic approaches

  • Xenograft models show PTPH1-dependent enhancement of breast cancer response to antiestrogens

  • Targeting the phospho-regulation machinery may benefit patients with wild-type ESR1 who develop non-genomic resistance mechanisms

The therapeutic potential of modulating this phosphorylation has been demonstrated in xenograft models, where PTPH1-mediated dephosphorylation enhanced sensitivity to antiestrogen therapy .

How do molecular dynamics simulations explain the differential effects of Tyr537 phosphorylation versus Y537S mutation on ESR1 conformation and function?

Molecular dynamics (MD) simulations provide critical insights into the structural and functional differences between Tyr537 phosphorylation and Y537S mutation effects on ESR1:

• Simulation methodology and parameters:

  • Crystal structures of TIF2-bound ER wild-type and Y537S mutant (PDB accession codes 1GWQ and 3Q95) serve as starting points

  • Ligands are removed to model the unliganded receptor state

  • Simulations are performed in explicit water boxes with physiological ion concentrations

  • Parameters include constant temperature (300K), pressure (1 atm), and CHARMM22 force field

• Conformational differences:

  • Y537S mutation effects:

    • Creates a novel hydrogen bond network that stabilizes the active conformation

    • Reduces conformational flexibility in the ligand-binding pocket

    • Maintains helix 12 in a position that favors coactivator binding even without estradiol

  • Phosphorylation effects:

    • Introduces a negative charge that alters local electrostatic interactions

    • May form different hydrogen bond networks than the serine substitution

    • Creates more dynamic conformational states than the stable Y537S mutation

• Functional implications from structural changes:

  • Both modifications stabilize active conformations but through different mechanisms:

    • Y537S provides constitutive activity through a stable structural reorganization

    • Phosphorylation offers regulatable activation that can be reversed by phosphatases

  • The Y537S mutation shows more robust resistance to antiestrogens than other mutations (Y537N/C)

  • The heightened stability of the Y537S active conformation explains why it typically confers the strongest phenotype among Y537 mutations

• Therapeutic design implications:

  • Different SERDs show varied effectiveness against specific Y537 mutations

  • Structure-based drug design can leverage simulation insights to develop compounds that destabilize mutant-specific conformations

  • Y537S requires agents that can overcome the enhanced stability of its active conformation

  • Novel compounds might be designed to specifically target the unique conformational features of either phosphorylated or mutant receptors

These computational insights explain clinical observations that Y537S mutations confer stronger constitutive activity and greater therapy resistance than other alterations at this position .

What is the clinical significance of detecting phospho-Tyr537 ESR1 in breast cancer biopsies?

Detection of phospho-Tyr537 ESR1 in breast cancer specimens has emerged as a clinically relevant biomarker with several important implications:

These findings support the incorporation of phospho-Tyr537 ESR1 assessment into comprehensive biomarker panels for breast cancer, potentially improving patient stratification and treatment selection .

How can multiplex detection of different phospho-ESR1 residues improve prediction of therapy response in breast cancer?

Multiplex detection of different phospho-ESR1 residues represents an advanced approach to comprehensively evaluate ESR1 activation status and improve therapy response prediction:

Research indicates that coordinated phosphorylation across multiple sites creates a "phosphorylation code" that more accurately reflects ESR1 activity and functional status than single-site analysis .

How does ctDNA detection of ESR1 mutations compare with tissue-based phosphorylation assessment in monitoring endocrine resistance?

The comparative utility of circulating tumor DNA (ctDNA) ESR1 mutation detection versus tissue-based phosphorylation assessment represents an important consideration in monitoring endocrine resistance:

• Sample accessibility and temporal considerations:

  • ctDNA advantages:

    • Minimally invasive liquid biopsies enable serial monitoring

    • Real-time assessment of evolving tumor populations

    • Potentially captures heterogeneity across multiple metastatic sites

  • Tissue phosphorylation advantages:

    • Provides spatial context and cellular localization information

    • Allows correlation with other tissue-based biomarkers

    • May detect functional changes before genetic alterations emerge

• Technical performance metrics:

  • ctDNA mutation detection:

    • Digital droplet PCR (ddPCR) enables sensitive detection of ESR1 hotspot mutations (Y537S/C/N, D538G, E380Q)

    • Concordance rate between tissue and plasma for ESR1 mutations is approximately 44%

    • Total concordance rate (including wild-type) reaches 91%

  • Phosphorylation assessment:

    • Requires adequate tissue specimens with preserved phospho-epitopes

    • Standardized scoring systems enable semi-quantitative assessment

    • May be affected by pre-analytical variables (ischemia time, fixation)

• Complementary information:

  • Mutation status:

    • Identifies specific mechanisms of constitutive activation

    • Provides actionable information for mutation-specific therapeutic approaches

    • May indicate cells committed to permanent resistance pathways

  • Phosphorylation status:

    • Reflects dynamic signaling states that may precede mutations

    • Indicates activation through non-genomic mechanisms

    • May identify reversible resistance mechanisms amenable to phosphatase activation

• Integrated monitoring strategy:

  • Initial comprehensive tissue assessment (mutation and phosphorylation status)

  • Serial ctDNA monitoring for emergence of known mutations

  • Repeat tissue analysis upon disease progression or treatment failure

  • Correlation of liquid and tissue biomarkers to improve interpretation

The different but complementary information provided by these approaches suggests an integrated strategy would provide the most comprehensive assessment of endocrine resistance mechanisms .